A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

NCT07281976 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: LBL-024 for Injection
DRUG: albumin-bound Paclitaxel injection
DRUG: Toripalimab Injection

Sponsor

Nanjing Leads Biolabs Co.,Ltd

Collaborators

[object Object]